All these ingredients are really good products to help reverse cataracts found in OcluMed
Available from: Lin J, Pearson SA, Greenfield JR, Park KH, Havard A, Brieger D et al (2023) Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (20142022)
Off-label prescriptions are a lot less likely to be covered by insurance plans, including those offered by Blue Cross Blue Shield
While these results show an association, not proof of cause and effect, they provide converging real-world evidence that #GLP1 therapies may offer benefits in IBD beyond metabolic disease and support further prospective study
Kicking that can down the road as far as possible has almost become an art form for brand drug companies with blockbuster products, engaging in a variety of anticompetitive tactics to lengthen their drugs exclusivity period and blocking cheaper competitor products from coming to market
That can introduce variability such as: Mislabeling Contamination Inconsistent dosing Unknown impurities Side effects: what we can responsibly say Because robust human safety data are limited, it's hard to give a definitive side-effect profile with meaningful incidence rates